The United States will allocate 85% fewer J&J vaccines to states next week, according to the data

(Reuters) – The U.S. government will allocate nearly 85 percent fewer Johnson & Johnson COVID-19 vaccines to states next week, according to Centers for Disease Control and Prevention (CDC).

Only 785,500 doses of J&J will be allocated, compared to 4.95 million doses this week. The U.S. Department of Health and Human Services (HHS) and J&J did not immediately respond to requests made outside of regular comment hours on the falling figures.

A New York Times report last week said workers at an Emergent BioSolutions facility in Baltimore, which produced doses of AstraZeneca Plc and J&J, were mixing ingredients from the two vaccines, ruining 15 million doses of J&J.

However, the Baltimore facility has not yet been authorized by the U.S. Food and Drug Administration and a federal health official told Reuters last week that none of the plant’s vaccine doses has been used so far in vaccination efforts.

J&J has reiterated that it expects to deliver 100 million doses to the government by the end of May.

According to CDC data, California is the main recipient of the J&J vaccine, followed by Texas and Florida. Vaccine allocation for California has dropped by about 88%, and the state is expected to receive only a maximum of 67,600 doses next week.

A California health official told Reuters that the number will drop further the week beginning April 18, with only 22,400 doses of the J&J vaccine allocated to the state.

U.S. President Joe Biden on Tuesday advanced the COVID-19 vaccine eligibility goal for all American adults through April 19th.